New team brings 50 years of combined Life Sciences experience to help company reach aggressive revenue goals while exceeding customer expectations

NEW YORK, NY–(Marketwired – June 27, 2017) – Prognos, an innovator in applying artificial intelligence (AI) to lab results, announces several strategic leadership appointments as the company enters a rapid growth stage.

The new additions to Prognos’ team are Chief Operating Officer Lisa Kerber, Chief Commercial Officer Stephen Silvestro and Chief Data Scientist Fernando Schwartz, Ph.D. With more than 50 years of combined Life Sciences experience, these industry veterans will take Prognos through “an intensive growth period and help further refine our AI and diagnostic data offerings by delving deeply into the market challenges facing Life Sciences executives,” said Sundeep Bhan, Co-Founder and CEO of Prognos.

“Adding seasoned professionals with diverse backgrounds is key in helping Prognos to scale and manage its rapid growth successfully,” Bhan added. “We are maintaining 90-percent renewal rates with our customers while capturing market share through innovation.”

As Chief Operating Officer at Prognos, Kerber is responsible for the company’s overall operations. Her specific focus is on leading the Life Sciences business line and overseeing strategic alliances with diagnostics partners as well as other partners in the healthcare ecosystem.

“After working primarily with claims and longitudinal prescription data, I was excited to work with a completely new asset, not previously available in a consumable or complete enough state for the Life Sciences industry,” said Kerber. “What makes this even more exciting is the recency and relevance of lab results information. It is oftentimes the beginning of the cascade of events that define a patient journey from disease to health.”

Kerber has more than two decades of experience supporting the Life Sciences industry and specializes in healthcare informatics and consulting services. Before joining Prognos, Kerber served in various roles at QuintilesIMS (formerly IMS Health) in Plymouth Meeting, Pa., for more than 20 years, most recently as US Vice President and General Manager, Real World Evidence. Kerber holds a bachelor degree from Temple University.

Bringing more than 15 years of strategic sales leadership to Prognos, Silvestro is building a world-class commercial function focused on empowering customers to maximize their own commercialization efforts and deliver true value to patients.

“Prognos is driving a significant change in Life Sciences by empowering brands to educate physicians more effectively to help improve patient outcomes,” said Silvestro. “Physicians are bombarded by messages that are often irrelevant for their specific patients, and Prognos’ ability to enable timely and accurate guidance at the time of decision is a radical shift in engagement between prescribers and the industry.”

Silvestro has held various sales roles at Burlington, Mass.-based Decision Resources Group, most recently as Executive Vice President, Head Global Sales. He holds a master’s degree in Business Management from Harvard University.

In his role as Chief Data Scientist at Prognos, Schwartz executes on the company’s healthcare AI vision through leading a team of highly motivated data scientists, analysts and engineers across geographies while directing the data science advisory board. He will also explore new markets and connect with customers for reference and potential data partnerships.

“I am excited to take many of the advanced analytic and machine learning techniques so common in the consumer advertising world and apply them to Prognos’ comprehensive diagnostics data asset,” said Schwartz. “It’s only a matter of time before AI enhances physician decision-making in dramatic ways, and Prognos can enable that kind of disease-predicting change.”

Prior to joining Prognos, Schwartz served as Chief Data Scientist at New York City-based LiveIntent, where he invented and deployed a market forecasting tool that generated a multi-million dollar lift in monthly booked revenue, leveraging AI and optimization algorithms. Prior to LiveIntent, Schwartz worked in data science at AppNexus, also in New York City, where he designed a budgeting algorithm in charge of allocating over $200 million of annual revenue through 20+ billion daily transactions. He holds a Ph.D. in Mathematics from Cornell University and has held postdoctoral positions at Duke University and the University of Warwick in Coventry, England.

To learn more about Prognos’ leadership and executive teams, read more about our team & advisors.

About Prognos

Prognos is an innovative healthcare AI company focused on eradicating disease by driving decisions earlier in healthcare in collaboration with Payers, Life Sciences and Diagnostics companies. It is the only company specializing in applying healthcare AI to clinical diagnostics. The Prognos Registry is the largest source of clinical diagnostics and lab information in 35 disease areas, with over 10 billion medical records for 160 million patients. Prognos has 900+ extensive proprietary and learning clinical algorithms to enable earlier patient identification for enhanced treatment decision-making, risk management and quality improvement. The company is supported by a $23M investment from Safeguard Scientifics, Inc. and Merck Global Health Innovation Fund (GHIF). For more information, visit

Text-Only Version